Autologous Adipose Tissue Derived Mesenchymal Stem Cells for Rotator Cuff Disease

Exclusion Criteria

• •Participants who met a single condition were excluded from the study
• •1. Patients who received any drug by subacromial injection for treatment within 3 months prior to this enrollment.
• •2. Patients who have a history of shoulder trauma including dislocation, subluxation, and fracture, breast cancer, or surgery around shoulder, neck and upper back within 6 months prior to this enrollment.
• •3. Patients who have a full-thickness rotator cuff tear
• •4. Patients who have radiological findings of malignancy, osteoarthritis of the glenohumeral joint, and skeletal abnormalities decreasing the subacromial space
• •5. Patients with symptomatic cervical spine disorders
• •6. Patients with concurrent bilateral shoulder pain
• •7. Patients with adhesive capsulitis, acromioclavicular arthropathy, polyarthritis, infectious arthritis, rheumatoid arthritis or diagnosed fibromyalgia
• •8. Patients with neurological deficit
• •9. Pregnant women or lactating mothers
• •10. Fertile woman of childbearing potential not willing to use adequate contraception for the study duration
• •11. Patients taking anticoagulants
• •12. Patients who are positive serology for human immunodeficiency (HIV), hepatitis B (HBV) or hepatitis C (HCV) and syphilis
• •13. Patients with serious condition which can affect this study such as severe cardiovascular diseases, renal diseases, liver diseases, endocrine diseases, and cancers
• •14. Patients who are difficulty participating in data collection due to communication problem and serious mental illness
• •15. Patients are unable to come into the clinic for regular follow-up
• •16. Patients who had participated in other clinical trials within 3 months prior to this study.
• •17. Patients who the principal investigator considered inappropriate for the clinical trial due to any other reasons than those listed above.